262 related articles for article (PubMed ID: 22158521)
41. Oncolytic herpes simplex virus treatment of metastatic breast cancer.
Wang J; Hu P; Zeng M; Rabkin SD; Liu R
Int J Oncol; 2012 Mar; 40(3):757-63. PubMed ID: 22108767
[TBL] [Abstract][Full Text] [Related]
42. A novel dendritic cell-based cancer vaccine produces promising results in a syngenic CC-36 murine colon adenocarcinoma model.
Jack AM; Aydin N; Montenegro G; Alam K; Wallack M
J Surg Res; 2007 May; 139(2):164-9. PubMed ID: 17275030
[TBL] [Abstract][Full Text] [Related]
43. VSV virotherapy improves chemotherapy by triggering apoptosis due to proteasomal degradation of Mcl-1.
Schache P; Gürlevik E; Strüver N; Woller N; Malek N; Zender L; Manns M; Wirth T; Kühnel F; Kubicka S
Gene Ther; 2009 Jul; 16(7):849-61. PubMed ID: 19369968
[TBL] [Abstract][Full Text] [Related]
44. Development of a second-generation oncolytic Herpes simplex virus expressing TNFalpha for cancer therapy.
Han ZQ; Assenberg M; Liu BL; Wang YB; Simpson G; Thomas S; Coffin RS
J Gene Med; 2007 Feb; 9(2):99-106. PubMed ID: 17256802
[TBL] [Abstract][Full Text] [Related]
45. Cancer upregulated gene 2, a novel oncogene, confers resistance to oncolytic vesicular stomatitis virus through STAT1-OASL2 signaling.
Malilas W; Koh SS; Srisuttee R; Boonying W; Cho IR; Jeong CS; Johnston RN; Chung YH
Cancer Gene Ther; 2013 Feb; 20(2):125-32. PubMed ID: 23306614
[TBL] [Abstract][Full Text] [Related]
46. Selective intratumoral amplification of an antiangiogenic vector by an oncolytic virus produces enhanced antivascular and anti-tumor efficacy.
Thorne SH; Tam BY; Kirn DH; Contag CH; Kuo CJ
Mol Ther; 2006 May; 13(5):938-46. PubMed ID: 16469543
[TBL] [Abstract][Full Text] [Related]
47. Immunological Effects and Viral Gene Expression Determine the Efficacy of Oncolytic Measles Vaccines Encoding IL-12 or IL-15 Agonists.
Backhaus PS; Veinalde R; Hartmann L; Dunder JE; Jeworowski LM; Albert J; Hoyler B; Poth T; Jäger D; Ungerechts G; Engeland CE
Viruses; 2019 Oct; 11(10):. PubMed ID: 31623390
[TBL] [Abstract][Full Text] [Related]
48. Potent systemic therapy of multiple myeloma utilizing oncolytic vesicular stomatitis virus coding for interferon-β.
Naik S; Nace R; Barber GN; Russell SJ
Cancer Gene Ther; 2012 Jul; 19(7):443-50. PubMed ID: 22522623
[TBL] [Abstract][Full Text] [Related]
49. Luciferase imaging for evaluation of oncolytic adenovirus replication in vivo.
Guse K; Dias JD; Bauerschmitz GJ; Hakkarainen T; Aavik E; Ranki T; Pisto T; Särkioja M; Desmond RA; Kanerva A; Hemminki A
Gene Ther; 2007 Jun; 14(11):902-11. PubMed ID: 17377596
[TBL] [Abstract][Full Text] [Related]
50. Enhanced oncolytic activity of vesicular stomatitis virus encoding SV5-F protein against prostate cancer.
Chang G; Xu S; Watanabe M; Jayakar HR; Whitt MA; Gingrich JR
J Urol; 2010 Apr; 183(4):1611-8. PubMed ID: 20172545
[TBL] [Abstract][Full Text] [Related]
51. Vaccine therapy of established tumors in the absence of autoimmunity.
Hodge JW; Grosenbach DW; Aarts WM; Poole DJ; Schlom J
Clin Cancer Res; 2003 May; 9(5):1837-49. PubMed ID: 12738742
[TBL] [Abstract][Full Text] [Related]
52. Enhanced antitumor efficacy of a novel oncolytic vaccinia virus encoding a fully monoclonal antibody against T-cell immunoglobulin and ITIM domain (TIGIT).
Zuo S; Wei M; He B; Chen A; Wang S; Kong L; Zhang Y; Meng G; Xu T; Wu J; Yang F; Zhang H; Wang S; Guo C; Wu J; Dong J; Wei J
EBioMedicine; 2021 Feb; 64():103240. PubMed ID: 33581644
[TBL] [Abstract][Full Text] [Related]
53. VSV-MP gene therapy strategy inhibits tumor growth in nude mice model of human lung adenocarcinoma.
Jing XM; Wen YJ; Shi W; Tang QQ; Li J; Chen XC
Cancer Gene Ther; 2012 Feb; 19(2):101-9. PubMed ID: 22052213
[TBL] [Abstract][Full Text] [Related]
54. IL-12 Expressing oncolytic herpes simplex virus promotes anti-tumor activity and immunologic control of metastatic ovarian cancer in mice.
Thomas ED; Meza-Perez S; Bevis KS; Randall TD; Gillespie GY; Langford C; Alvarez RD
J Ovarian Res; 2016 Oct; 9(1):70. PubMed ID: 27784340
[TBL] [Abstract][Full Text] [Related]
55. The potential of recombinant vesicular stomatitis virus-mediated virotherapy against metastatic colon cancer.
Yamaki M; Shinozaki K; Sakaguchi T; Meseck M; Ebert O; Ohdan H; Woo SL
Int J Mol Med; 2013 Feb; 31(2):299-306. PubMed ID: 23232984
[TBL] [Abstract][Full Text] [Related]
56. Re-engineering vesicular stomatitis virus to abrogate neurotoxicity, circumvent humoral immunity, and enhance oncolytic potency.
Muik A; Stubbert LJ; Jahedi RZ; Geiβ Y; Kimpel J; Dold C; Tober R; Volk A; Klein S; Dietrich U; Yadollahi B; Falls T; Miletic H; Stojdl D; Bell JC; von Laer D
Cancer Res; 2014 Jul; 74(13):3567-78. PubMed ID: 24812275
[TBL] [Abstract][Full Text] [Related]
57. Sensitivity of cervical carcinoma cells to vesicular stomatitis virus-induced oncolysis: potential role of human papilloma virus infection.
Le Boeuf F; Niknejad N; Wang J; Auer R; Weberpals JI; Bell JC; Dimitroulakos J
Int J Cancer; 2012 Aug; 131(3):E204-15. PubMed ID: 22173567
[TBL] [Abstract][Full Text] [Related]
58. Vesicular stomatitis virus-induced immune suppressor cells generate antagonism between intratumoral oncolytic virus and cyclophosphamide.
Willmon C; Diaz RM; Wongthida P; Galivo F; Kottke T; Thompson J; Albelda S; Harrington K; Melcher A; Vile R
Mol Ther; 2011 Jan; 19(1):140-9. PubMed ID: 20978474
[TBL] [Abstract][Full Text] [Related]
59. Exponential enhancement of oncolytic vesicular stomatitis virus potency by vector-mediated suppression of inflammatory responses in vivo.
Altomonte J; Wu L; Chen L; Meseck M; Ebert O; García-Sastre A; Fallon J; Woo SL
Mol Ther; 2008 Jan; 16(1):146-53. PubMed ID: 18071337
[TBL] [Abstract][Full Text] [Related]
60. Superagonist IL-15-Armed Oncolytic Virus Elicits Potent Antitumor Immunity and Therapy That Are Enhanced with PD-1 Blockade.
Kowalsky SJ; Liu Z; Feist M; Berkey SE; Ma C; Ravindranathan R; Dai E; Roy EJ; Guo ZS; Bartlett DL
Mol Ther; 2018 Oct; 26(10):2476-2486. PubMed ID: 30064894
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]